• SPX
  • $5,965.89
  • 0.29 %
  • $17.18
  • DJI
  • $44,211.99
  • 0.78 %
  • $341.63
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,262.08
  • 1.38 %
  • $112.81
  • IXIC
  • $18,994.03
  • 0.11 %
  • $21.61
Enzo Biochem, Inc. (ENZ) Stock Price, News & Analysis

Enzo Biochem, Inc. (ENZ) Stock Price, News & Analysis

Currency in USD Disclaimer

$0.97

-$0

(-0.07%)

Day's range
$0.97
Day's range
$0.99
50-day range
$0.9602
Day's range
$1.19
  • Country: US
  • ISIN: US2941001024
52 wk range
$0.96
Day's range
$1.5


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -3.13
  • Piotroski Score 2.00
  • Grade Buy
  • Symbol (ENZ)
  • Company Enzo Biochem, Inc.
  • Price $0.97
  • Changes Percentage (-0.07%)
  • Change -$0
  • Day Low $0.97
  • Day High $0.99
  • Year High $1.50

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing ‘STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.

  • Last Earnings 10/29/2024
  • Ex-Dividend for 5/16 Dividend 11/15/2024
  • Dividend Payable 12/02/2024
  • Today N/A
  • Next Earnings (Estimated) 12/13/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.47
  • Trailing P/E Ratio -2.4
  • Forward P/E Ratio -2.4
  • P/E Growth -2.4
  • Net Income $-26,078,000

Income Statement

Quarterly

Annual

Latest News of ENZ

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Enzo Biochem, Inc. Frequently Asked Questions

  • What were the earnings of ENZ in the last quarter?

    In the last quarter Enzo Biochem, Inc. earnings were on Monday, June, 10th. The Enzo Biochem, Inc. maker reported -$0.14 EPS for the quarter, beating analysts' consensus estimates of -$0.15 by $0.01.

  • What is the Enzo Biochem, Inc. stock price today?

    Today's price of Enzo Biochem, Inc. is $0.97 — it has decreased by -0.07% in the past 24 hours. Watch Enzo Biochem, Inc. stock price performance more closely on the chart.

  • Does Enzo Biochem, Inc. release reports?

    Yes, you can track Enzo Biochem, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Enzo Biochem, Inc. stock forecast?

    Watch the Enzo Biochem, Inc. chart and read a more detailed Enzo Biochem, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Enzo Biochem, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NYSE, exchange stock trades by Enzo Biochem, Inc. stock ticker.

  • How to buy Enzo Biochem, Inc. stocks?

    Like other stocks, ENZ shares are sold on stock exchanges such as NYSE. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Enzo Biochem, Inc.'s EBITDA?

    Enzo Biochem, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Enzo Biochem, Inc.’s financial statements.

  • What is the Enzo Biochem, Inc.'s net income ratio for the financial year 2024?

    The net income ratio for the financial year 2024 is -0.8173128154, which equates to approximately -81.73%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Enzo Biochem, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Enzo Biochem, Inc.'s financials relevant news, and technical analysis. Enzo Biochem, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Enzo Biochem, Inc. stock currently indicates a “sell” signal. For more insights, review Enzo Biochem, Inc.’s technical analysis.

  • A revenue figure for Enzo Biochem, Inc. for its last quarter?

    Enzo Biochem, Inc. published it's last quarterly revenues at $7.53 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.